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G-proteinTungstate treatment ameliorates experimental diabetes by increasing liver glycogen deposition
through an as yet unidentiﬁed mechanism. The signalling mechanism of tungstate was studied in
CHOIR cells and primary cultured hepatocytes. This compound exerted its pro-glycogenic effects
through a new G-protein-dependent and Tyr-Kinase Receptor-independent mechanism. Chemical
or genetic disruption of G-protein signalling prevented the activation of the Ras/ERK cascade and
the downstream induction of glycogen synthesis caused by tungstate. Thus, these ﬁndings unveil
a novel non-canonical signalling pathway that leads to the activation of glycogen synthesis and that
could be exploited as an approach to treat diabetes.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction pancreatic b-cell population in neonatally STZ-induced rats, aThe potential of sodium tungstate for the treatment of diabetes
has been well documented in several animal models of type 1 and
2 diabetes. When administered orally to diabetic animals, this
compound reduces and, in most cases, normalizes glycaemia, and
remarkably does not cause hypoglycaemia [1–3]. In STZ (streptozo-
tocin-induced) diabetic rats, tungstate treatment restores hepatic
glucose metabolism [2,4] and increases the total amount and
translocation of GLUT4 in muscle through a mechanism associated
with ERK (extracellular signal-regulated kinases 1 and 2) [5]. It also
markedly reduces hypertriglyceridemia in ZDF (Zucker Diabetic
Fatty) rats [3]. In addition, treatment with this compound stimu-
lates insulin secretion [1,6] and regenerates a stable, functionalmodel of type 2 diabetes [1,7].
Despite considerable data on the pharmacological and
metabolic effects of tungstate, little information is available on
its molecular mechanisms of action. The ﬁrst results showed that
tungstate increases glycogen deposition in primary cultured
hepatocytes, thereby exerting insulin-like actions in these cells.
Analysis of the effects of this compound on several components
of the insulin signalling transduction cascade demonstrated that
these effects are not mediated by the insulin receptor (IR) as the
phosphorylation state of this receptor remains unchanged after
treatment. In contrast, a clear transient phosphorylation of ERK is
detected [8]. Tungstate also triggers the phosphorylation of
p90rsk and glycogen synthase kinase-3b (GSK3b), and the activa-
tion of glycogen synthase (GS), but independently of protein kinase
B (PKB) activation. These effects are blocked by inhibitors of ERK
activation, thereby indicating that this kinase plays a key role in
tungstate-stimulated glycogen synthesis in liver and therefore
contributes to the insulin-like actions of this compound [8]. More-
over, tungstate also stimulates ERK phosphorylation in diverse cell
types, such as Leydig cells and neurons [9–10].
However, the primary targets of tungstate are unknown. Here
we analysed the effects of tungstate upstream of ERK. Our results
show that tungstate activates glycogen synthesis through a novel
non-canonical mechanism involving G-proteins.
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2.1. Materials
Sodium tungstate was from Carlo Erba (Milan, Italy). Tissue cul-
ture media and supplements were from Sigma (St. Louis, MO, USA)
and Invitrogen (Carlsbad, CA, USA). Fetal Calf Serum (FCS) was from
Biological Industries (Ashrat, Israel). ERK antibody was from
Upstate (Waltham, MA, USA). Phospho-GSK3a/b (Ser 21/9),
phospho-ERK (Thr 202/Tyr 204), phospho-p90rsk (Ser 380), phos-
pho-GS (Ser 641) antibodies were purchased from Cell Signalling
(Beverly, MA). Phospho-PKB (Ser 473) antibody was from Nano-
Tools (Teningen, Germany). Ras antibody was supplied by Onco-
gene Research Products (San Diego, CA, USA). HRP-conjugated
secondary antibodies were from Cell Signalling or Jackson Immu-
noresearch Labs (West Grove, PA, USA). Enzymes and biochemical
reagents were purchased from Sigma, unless otherwise indicated.
All other chemicals were of analytical grade.
2.2. Cell culture
Chinese hamster ovary (CHO) cells stably transfected with the
human wild-type insulin receptor (CHOIR) [11] were cultured in
Ham’s F-12 nutrient mixture supplemented with 10% FCS and
0.7 mg/ml Geneticin. HaCaT cells were maintained in DMEM con-
taining FCS (10%). Cells were grown to conﬂuence and then de-
prived of FCS for 16–18 h. Tungstate and insulin treatments were
performed in serum-free medium unless otherwise indicated.
Plates were ﬂash frozen in liquid nitrogen and processed for pro-
tein extract preparation as described [8].
The procedure to obtain primary rat hepatocytes was approved
by the institutional Animal Experimentation Committee and car-
ried out in accordance with the guidelines of the European Com-
munity Council Directive for the care and use of laboratory
animals. Collagenase perfusion was used to isolate hepatocytes
from male Wistar rats (180–225 g) previously fasted for 12 h, as
described [12]. Hepatocytes were suspended in DMEM supple-
mented with 10 mM glucose, 10% FCS, 100 nM insulin and
100 nM dexamethasone, seeded onto 60-mm diameter plastic
plates and processed as described [8].
2.3. Western blot analysis
Cells were grown to conﬂuence and then deprived of FCS for
16–18 h. Tungstate and insulin treatments were performed in
serum-free medium unless otherwise indicated. Plates were ﬂash
frozen in liquid nitrogen and processed for protein extract prepara-
tion. Protein concentration was measured using the BCA Protein
Assay (Pierce, USA). Proteins were separated by SDS–PAGE loading
20 lg of total protein per lane, transferred to nitrocellulose mem-
branes (Schleicher and Schuell, Dassel, Germany) and immunoblot-
ted with selected antibodies; the immunoblots were developed
using an enhanced chemiluminescence detection system (GE
Healthcare, UK).
2.4. Endogenous Ras activation assay
Activated Ras (Ras-GTP) was determined using glutathione-S-
transferase (GST) pull-down assay, as described [13]. Brieﬂy, cell
lysates were clariﬁed by centrifugation at 10,000 g for 10 min,
and 1 mg of total proteins from the supernatants was incubated
with glutathione-Sepharose beads (Amersham Biosciences). The
beads were freshly coupled to GST-Raf1-RBD to isolate Ras-GTP.
Bound proteins were eluted with SDS–PAGE sample buffer, re-
solved on 13% acrylamide gels and subjected to Western blottingwith anti Ras antibody. A fraction of the raw lysate was used to
determine the amount of total Ras.
2.5. Glycogen measurement
To measure glycogen content, hepatocyte monolayers were
scraped into 30% KOH. The extracts were heated at 100 C for
15 min. Glycogen was measured in the heated extracts, as de-
scribed [14].
2.6. Transfection experiments
Brieﬂy, CHOIR cells were plated 24 h before transfection at a
density of 1  106 cells/100 mm plate and were then transfected
by electroporation with GFP plasmid pEGFP-C1 (Clontech, Moun-
tain View, CA, USA) or the construct designated as pcDNA-CD8-
bARK-C (CD8-bARK). CD8-bARK expresses the extracellular and
transmembrane domains of CD8 (lymphocyte-speciﬁc receptor)
fused to an intracellular domain containing the bc binding portion
of human bARK and a COOH-terminal Myc epitope [15] (a kind gift
from Dr. F. Mayor Jr. (CBM, Madrid, Spain)). Cells were incubated in
medium containing 10% FCS until they reached conﬂuence. They
were then starved in FCS-free medium for 16–18 h and ﬁnally trea-
ted with 1 mM tungstate or 100 nM insulin for the times indicated
in the ﬁgures.
2.7. Virus generation and infection
The strategy followed for adenovirus generation was based on
that described by Becker et al. [16], with some modiﬁcations
[17]. Brieﬂy, the dominant negative form of human H-Ras
(RasN17) (a kind gift from Dr. Pellicer, NYU Cancer Institute,
NY) cloned in pcDNA3.1/Zeo/BamH1 was subcloned in the
KpnI/XbaI sites of the pACC vector. Subconﬂuent CHOIR cells or
freshly prepared hepatocytes were treated with AdRasN17 or
AdGFP in FCS-free DMEM for 2 h, at a multiplicity of infection
(MOI) of 10. The medium was then replaced by Ham’s F-12 with
10% FCS in the case of CHOIR cells and by glucose-free DMEM in
the case of hepatocytes. Cells were kept in these conditions for
16–18 h. The treatments with insulin or tungstate were per-
formed as described above.
Human shRNA-expressing lentiviral plasmids were purchased
from Sigma. 293T cells were transfected with 5 lg/150 mm dish
of pRRE, pRSV rev, pHCMV-VSV-G and the plasmid expressing
the shRNA of interest using polyethylenimine (PEI). After 48 and
72 h of transfection, cell culture media were collected and used
to infect human HaCaT cells. After 48 h of infection, positive cells
were selected with 2 lg/ml puromycin.
2.8. Real-time PCR
RNA extraction and Reverse Transcription were performed
using RNeasy™ Mini Kit from Qiagen (Düsseldorf, Germany) and
SuperScript™ III First-Strand from Invitrogen (Carlsbad, CA, USA),
respectively, and following the manufacturers’ instructions.
TaqMan probes and Universal Master Mix for Real-Time PCR were
purchased from Applied Biosystems (Foster City, CA, USA). For
detection, we used a 7900HT Sequence Detection System from
Applied Biosystems.
2.9. Statistical analysis
To determine signiﬁcance, analysis of variance and unpaired
Student’s t test were performed. P < 0.05 was considered
signiﬁcant.
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Our ﬁrst approach was to study the effects of tungstate in
CHOIR cells. This is a suitable cellular model to analyse the down-
stream events of the insulin transduction cascade, in which tung-
state was demonstrated to activate ERK signalling without
affecting the IR. We then validated our results using primary cul-
tured rat hepatocytes, since deposition of liver glycogen is a hall-
mark of tungstate insulin-like effects.
3.1. Sodium tungstate activates Ras in CHOIR cells
By means of Western blot analysis using phospho-speciﬁc anti-
bodies, we studied the effects of tungstate on the enzymes up-
stream of ERK. We examined the effect of tungstate treatment on
mitogen-activated protein kinase kinase (MEK), the main kinase
involved in the phosphorylation of ERK, and on Raf, which lies up-
stream of MEK. Tungstate increased the phosphorylation of both
proteins in residues responsible for the activation of these kinases
(data not shown). We next studied the upstream effector of c-Raf,
the small GTPase Ras. Pull-down activity assays showed a clear
activation of this protein when CHOIR cells were treated with
tungstate (Fig 1A and B). The scarcity of Ras inhibitors and their
poor effectiveness prompted us to generate an adenovirus coding
for a dominant negative form of Ras, named RasN17. In cells
expressing RasN17, the effect of tungstate on ERK phosphorylation
was blocked (Fig 1C). Given that ERK phosphorylation induced by
insulin in RasN17-expressing cells was also inhibited and in order
to exclude a non-speciﬁc effect on phosphorylation caused by
RasN17 expression, we tested whether other components of the
insulin signalling cascade that are not related to Ras activation
were affected. In this regard, in RasN17-expressing cells, the phos-
phorylation of PKB induced by insulin was not affected (Fig 1C),
thus conﬁrming the speciﬁcity of RasN17 effects. However, tung-
state-induced phosphorylation of GSK3a/b was reduced in cells in-
fected with adenovirus expressing RasN17 (Fig 1C and D). TheseFig. 1. Upstream effects of tungstate on the ERK pathway in CHOIR cells. (A) Ras activit
PDGF was used as a positive control of Ras activation in CHOIR cells. (B) Densitometric a
(n = 5). (C) CHOIR cells were infected for 2 h with AdRasN17 or with AdGFP. After infectio
FCS-starved for 16–18 h. Cell extracts were analysed by Western blot with phospho-ERK,
Densitometric analysis of phospho-GSK3a/b in CHOIR cells treated as in (C) (n = 5). In all
the times indicated. Densitometric data is expressed as mean ± S.E. ⁄P < 0.05, ⁄⁄P < 0.01.results provide evidence supporting that tungstate induces phos-
phorylation of GSK3a/b in a Ras-dependent manner, and indepen-
dently of the PI3 K and PKB pathways. Furthermore, when CHOIR
cells were infected with an adenovirus expressing GFP, the stimu-
latory effect of tungstate on ERK phosphorylation was unaffected.
Taken together, these results support a requirement of Ras activa-
tion for tungstate-mediated phosphorylation of ERK.
3.2. Involvement of G-proteins in the tungstate-mediated activation of
Ras and phosphorylation of ERK in CHOIR cells
In a previous study using antibodies against phospho-tyrosine
residues, we showed that tungstate treatment does not induce
the phosphorylation of the IR in CHOIR cells [8] or of other Recep-
tor Tyr Kinase (RTKs). In the present study we conﬁrmed this
observation using phospho-speciﬁc antibodies against the IR, the
EGF Receptor and the IGF Receptor (data not shown).
Thus, we considered RTK-independent mechanisms for the acti-
vation of the Ras/ERK pathway by tungstate treatment. We exam-
ined whether G-proteins were involved in tungstate-induced
phosphorylation of ERK. CHOIR cells pre-incubated for 28 h with
pertussis toxin (PTX), a G-protein inhibitor that ADP-ribosylates
the alpha subunits of the heterotrimeric guanine nucleotide regu-
latory proteins Gai, Gao and Gat, showed a blockade of tungstate-
induced Ras activation and ERK phosphorylation (Fig 2A and B).
Moreover, phosphorylation of GSK3a/b induced by tungstate was
also inhibited in cells treated with PTX (Fig 2A and B). We extended
our results by knocking down the distinct Ga subunits sensitive to
PTX (Gao, Gai1, Gai2 and Gai3) with shRNA-expressing lentivirus-
es. ERK phosphorylation stimulated by tungstate was not affected
after a 90% decrease in Gao expression (data not shown), thus
ruling out the involvement of Gao in the mechanism of action of
this compound. In contrast, the silencing of the Gai subunits im-
paired the capacity of tungstate to induce ERK phosphorylation.
This effect was abolished in Gai2 knock-down cells (Fig 2C, D
and E) and was reduced, but to a lesser extent, in Gai1 and Gai3y assay. Cells were treated with insulin, tungstate or PDGF for the times indicated.
nalysis of Active Ras in CHOIR cells treated with insulin, tungstate or PDGF as in (A)
n, cells were incubated in Ham’s F-12 medium supplemented with 10% FCS and then
phospho-PKB, phospho-GSK3a/b (indicated by arrows) and total Ras antibodies. (D)
cases, cells were treated with 100 nM insulin, 1 mM tungstate or 20 ng/ml PDGF for
Fig. 2. Involvement of G-proteins in the mechanism of action of tungstate. (A) Ras-GTP pull-down assay in CHOIR cells pretreated with 100 ng/ml PTX for 28 h. Afterwards,
insulin or tungstate was added to the medium until concentrations reached 100 nM or 1 mM, respectively. Cell extracts were used to analyse the phosphorylation state of
GSK3a/b and ERK and the total amount of Ras in response to insulin or tungstate. (B) Densitometric analysis of Active Ras, phospho-GSK3a/b and phospho-ERK in CHOIR cells
treated as in (A) (n = 5). (C) Analysis of Gai2 expression by Real-Time PCR in HaCaT cells in which the PTX-sensitive Gai2 subunit was silenced. The bar graph represents the
percentage of expression of the gene of interest compared to cells infected with a scrambled-shRNA lentivirus (SC). (D) Western blot analysis of phosphorylated ERK in HaCaT
cells infected with the lentivirus expressing the SC or the Gai2 shRNA, and then treated with 100 ng/ml EGF or 1 mM tungstate for the times indicated. (E) Densitometric
analysis of phospho-ERK in HaCaT cells treated as in (D) (n = 4). (F) Western blot analysis of phosphorylated ERK in CHOIR cells transfected with CD8-bARK or with a GFP
vector (pEGFP-C1) and then treated with 100 nM insulin or 1 mM tungstate for the times indicated. (G) Densitometric analysis of phospho-ERK in CHOIR cells treated as in (F)
(n = 4). Data is expressed as mean ± S.E.⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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expressing CD8-bARK, used as a blocking molecule for bc subunits
[15], showed reduced ERK phosphorylation in response to tung-
state treatment (Fig 2F and G), thus indicating the involvement
of bc subunits in the effects of this compound on ERK phosphory-
lation. Consequently, both Gai and bc subunits play a crucial role
in the mechanism of action of tungstate.
3.3. Effects of tungstate on primary cultured rat hepatocytes
We next examined whether the tungstate actions described
here for CHOIR cells also occurred in primary cultured hepatocytes,
which are among the main targets of this compound in vivo. Ras
pull-down assays in hepatocytes showed activation of Ras by tung-
state (Fig 3A and B). Moreover, RasN17 expression in hepatocytes
reduced other tungstate-induced downstream events, such as
ERK and GSK3a/b phosphorylation, without affecting PKB phos-
phorylation (Fig 3C). Tungstate-induced GSK3 phosphorylation in
cells infected with AdRasN17 was signiﬁcantly reduced compared
to control cells (Fig 3D). As observed in CHOIR cells, tungstate in-
duces phosphorylation of GSK3a/b in a Ras-dependent manner,
and independently of the PI3K and PKB pathways, also in hepato-
cytes. In order to examine whether G-proteins were also involved
in tungstate-mediated glycogen accumulation in hepatocytes, we
incubated these cells with PTX in the presence of glucose. Thistreatment blocked the stimulation of glycogen deposition induced
by tungstate (Fig 4A). PTX treatment also abolished tungstate-
stimulated ERK phosphorylation (Fig 4B, upper panel, and Fig
4C). Moreover, we studied the phosphorylation of GS in Ser 641,
a residue phosphorylated by GSK3 (Fig 4B, lower panel). Densito-
metric analysis showed that tungstate decreased phosphorylation
on that residue (Fig 4D), thereby indicating the activation of GS
and consequently of glycogen synthesis. In hepatocytes treated
with PTX, tungstate did not induce the dephosphorylation of GS
on this residue. Therefore, the effects of tungstate in primary cul-
tured hepatocytes are analogous to those exerted in CHOIR cells
and indicate that G-proteins also play a central role in the mecha-
nism of action of tungstate in hepatocytes.4. Discussion
Here we present a new pathway to activate glycogen synthesis.
This new route involves G-proteins and the subsequent activation
of the Ras/ERK pathway, but it is independent of the classical insu-
lin-activated pathway involving the IR. A previous study performed
by our group [8] identiﬁed a ﬁrst set of proteins involved in the
tungstate-induced increase in glycogen deposition in hepatocytes.
The ERK activation induced by this compound leads to the
phosphorylation (inactivation) of GSK3, which results in GS
Fig. 3. Effects of sodium tungstate on Ras in primary cultured rat hepatocytes. (A) Ras activity assay of hepatocytes treated with 100 nM insulin or 1 mM tungstate in 30 mM
glucose medium for the times indicated. (B) Densitometric analysis of Active Ras in hepatocytes treated as in (A) (n = 4). (C) Hepatocytes were infected with AdRasN17 or with
AdGFP for 2 h. After infection, cells were incubated for 16–18 h in glucose-free DMEM. During the experiment, cells were incubated with 100 nM insulin, 100 ng/ml EGF or
1 mM tungstate in DMEM with 30 mM glucose for the times indicated. Cell extracts were analysed by Western blot with the phospho-ERK, phospho-GSK3a/b, phospho-PKB
and total Ras antibodies. (D) Densitometric analysis of phospho-GSK3a/b in hepatocytes treated as in (C) (n = 3). Data is expressed as mean ± S.E. ⁄P < 0.05, ⁄⁄P < 0.01.
Fig. 4. Involvement of G-proteins in the mechanism of action of tungstate in primary cultured rat hepatocytes. (A) Hepatocytes were pre-incubated in DMEMwithout glucose
in the absence or presence of 100 ng/ml PTX for 20 h. Glycogen accumulation was measured after 3 h of incubation with or without 30 mM glucose and/or 1 mM tungstate.
Glycogen content is expressed as lg of glucose/mg of protein. #, P < 0.05 compared with 1 mM tungstate without PTX. The graph is representative of three independent
experiments with 2–4 samples (plates) for each condition. (B) Cell extracts from each condition were used to analyse the phosphorylation of ERK at Thr 202 and Tyr 204
residues and glycogen synthase at Ser 641. Densitometric analysis of phospho-ERK (C) and phospho-GS (D) in hepatocytes treated as in (B) (n = 5). Data is expressed as
mean ± S.E. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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thermore, we showed that tungstate did not alter the phosphory-
lation state of the IR, thus suggesting that this compound exerts
its action through an IR-independent mechanism.Therefore, the question remained as to the primary target/s of
tungstate action. The present study addresses this issue through
an analysis of the activation state of signal transducers upstream
of ERK. We show that the upstream protein Ras was activated in
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through the previous activation of RTKs and guanine nucleotide ex-
change factors (GEFs) [18]. However, we collected evidence that
excluded the involvement of RTKs in the mechanism of action of
tungstate. As signalling through heterotrimeric G-proteins acti-
vates Ras GTPase and ERK [15,19], we evaluated the involvement
of G-proteins in the mechanism of action of tungstate.
Our results show that treatment with PTX and the knock down
of the Gai2 subunit of G-proteins completely blocked tungstate-
induced Ras activation and ERK phosphorylation. The inhibition
of ERK phosphorylation observed in Gai2 knock-down cells
suggests that this isoform plays a prominent role in the cellular re-
sponse to tungstate. In this regard, it has been described that a
deﬁciency of the Gai2 subunit impairs insulin action. Gai2
deﬁciency in adipose tissue and liver produces hyperinsulinemia,
impaired glucose tolerance and insulin resistance in vivo [20].
Moreover, the expression of a constitutively active mutant of
Gai2 mimics insulin action in vivo [21]. Therefore, the activation
of Gai2 by tungstate may contribute to the improvement of the
diabetic state observed in the treated animals. Gi proteins signal
ERK activation not only through Ga subunits but also through
Gbc subunits [15] and their downstream effectors [22]. The
Gbc-mediated activation of ERK involves Ras [19,23]. Given that
CD8-bARK, a chimeric molecule that sequesters Gbc subunits to
the inner side of the membrane, also blocks tungstate-induced
ERK phosphorylation, it is conceivable that both Gai2 and Gbc
subunits participate in the mechanism of action of tungstate.
One of the most relevant ﬁndings of this study is that disruption
of G-protein signalling also prevented tungstate-induced ERK
phosphorylation and glycogen deposition in hepatocytes. This
observation thus links the proposed mechanism of action with
one of the main therapeutic activities of tungstate. Indeed, en-
hanced liver glycogen deposition has been shown to ameliorate
hyperglycaemia in rat models of diabetes [24–25].
In conclusion, here we describe a novel mechanism for the acti-
vation of hepatic glycogen deposition through which tungstate ex-
erts its anti-diabetic actions. This mechanism does not involve
RTKs but rather G-proteins. These ﬁndings thus reveal an innova-
tive link between these proteins, ERK phosphorylation, and the
stimulation of glycogen deposition, and point to G-proteins as
potential targets for the design of anti-diabetic agents.Funding
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